Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer
May 11, 2020 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, May 11, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 19
May 07, 2020 16:01 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, May 07, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism
April 19, 2020 16:00 ET
|
Ascendis Pharma
– PaTH Forward Trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks –– Conference call today at 6 p.m. Eastern Time to...
Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States
April 15, 2020 16:58 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, April 15, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
Ascendis Pharma A/S Reports Full-Year 2019 Financial Results
April 01, 2020 16:01 ET
|
Ascendis Pharma
– On track with 2020 corporate milestones – – Top-line data from PaTH Forward phase 2 trial on track for mid-April – – Conference call today at 4:30 p.m. Eastern Time – COPENHAGEN,...
Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1
March 25, 2020 16:01 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, March 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Announces Upcoming Investor Presentation in February
February 12, 2020 16:01 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference
January 12, 2020 19:45 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference
January 09, 2020 16:00 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results
November 18, 2019 16:01 ET
|
Ascendis Pharma
– Continued execution of global endocrinology rare disease programs as planned regulatory filings for TransCon™ hGH in 2020 advance on track – – Expanded PaTH Forward Trial expedites enrollment of...